The Direction of the Clostridioides difficile –Gastrointestinal GVHD Relationship After Allogenic Hematopoietic Cell Transplantation: A Time‐Dependent CIBMTR Analysis
Open Access
- 29 October 2026
- journal article
- Published by Wiley in Transplant Infectious Disease
Abstract
Background: Clostridioides difficile infection (CDI) and gastrointestinal acute graft‐versus‐host disease (GI‐GVHD) frequently co‐occur after allogeneic hematopoietic cell transplantation (allo‐HCT), and a bidirectional relationship has been proposed. The prior CIBMTR analysis associated antecedent GI‐GVHD with CDI but modeled GI‐GVHD as a fixed exposure and could not test whether CDI predicts subsequent GI‐GVHD. Methods: We analyzed a publicly available CIBMTR dataset of patients undergoing first allo‐HCT for AML, ALL, or MDS (2013–2018), each complication was modeled as a time‐dependent exposure using cause‐specific Cox regression, with death and relapse treated as competing events, adjusting for donor type, disease, conditioning intensity, and (reverse direction) GVHD prophylaxis type. Sensitivity analyses included restriction to adults and exclusion of CDI diagnosed before post‐transplant cyclophosphamide PTCy. Results: CDI within 100 days occurred in 777 patients (11%). CDI did not predict subsequent GI‐GVHD (HR 1.15; 95% CI 0.90–1.48; p = 0.26). GI‐GVHD predicted subsequent CDI (HR 1.54; 95% CI 1.08–2.19; p = 0.016), unchanged after adjustment for prophylaxis type and stronger in adults (HR 1.73; 95% CI 1.18–2.55). An apparent PTCy–CDI association (HR 1.38; 95% CI 1.08–1.75; p = 0.009), was driven by CDI with onset by Day 4, before PTCy, and was no longer significant once excluded (HR 1.11; 95% CI 0.80–1.52). Conclusions: When event timing and competing risks are respected, the GI‐GVHD predicts subsequent CDI whereas the reverse is not observed. GI‐GVHD identifies patients at elevated risk who are candidates for heightened surveillance. The disappearance of the PTCy signal once drug timing was respected illustrates how event ordering can misattribute risk.Keywords
This publication has 11 references indexed in Scilit:
- Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10)eClinicalMedicine, 2025
- Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisNew England Journal of Medicine, 2023
- Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic TransplantationTransplantation and Cellular Therapy, 2021
- Microbiome-intestine cross talk during acute graft-versus-host diseaseBlood, 2020
- Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA MatchingTransplantation and Cellular Therapy, 2020
- Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment PeriodTransplantation Direct, 2017
- Clostridium Difficile Infection in the Hematopoietic Unit: A Meta-Analysis of Published StudiesTransplantation and Cellular Therapy, 2014
- Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemiaBone Marrow Transplantation, 2013
- Clostridium difficile Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and OutcomeTransplantation and Cellular Therapy, 2012
- Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortalityBone Marrow Transplantation, 2000